Business Context and Reporting Period
This Form 8-K Current Report was filed by Corbus Pharmaceuticals Holdings, Inc. (CRBP) on March 6, 2023, covering events occurring on March 1, 2023. The filing primarily addresses corporate governance changes, specifically the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel appointments and does not contain financial performance data.
Material Changes
The material change reported is the appointment of Yong Ben, M.D., MBA, to the Board of Directors. Dr. Ben brings over 20 years of clinical development expertise, including strategic planning and oncology clinical trial design. His prior roles include Chief Medical Officer at BeiGene, Ltd. and BioAtla, Inc., and Global Clinical Leader at AstraZeneca PLC.
Compensation and Governance Details
- Compensation: Dr. Ben will receive an initial option grant to purchase 5,307 shares of common stock, an annual cash retainer of $40,000 (pro-rated for the current year), and an annual stock option grant.
- Indemnification: The Company entered into a standard indemnification agreement with Dr. Ben, obligating the Company to indemnify him for certain expenses incurred in his capacity as a director.
- Disclosure: A press release regarding this appointment was issued on March 6, 2023, under Regulation FD.
Investor Verification Checklist
- Verify the exact terms of the initial option grant (exercise price and vesting schedule) in the Company's proxy statements or subsequent filings.
- Review the Company's most recent 10-K or 10-Q for current financial health, as this 8-K contains no financial data.
- Confirm the total number of board seats and the composition of the Board following this appointment.
- Check for any related party transactions involving Dr. Ben's current employer, Eight Roads Venture, in future filings.